8-K: BioAge BGE-102 Shows Best-in-Class Potential in Phase 1

BioAge Labs announced positive interim Phase 1 data for BGE-102, demonstrating significant reduction in inflammatory markers for cardiovascular risk.

Summary

• BioAge Labs reported additional positive interim Phase 1 data for BGE-102, a novel brain-penetrant NLRP3 inhibitor.
• In a multiple ascending dose (MAD) cohort of obese participants with elevated hsCRP, BGE-102 (120 mg once daily) achieved an 86% median reduction in high-sensitivity C-reactive protein (hsCRP) at Day 14.
• Notably, 93% of BGE-102-dosed participants (13 of 14) reached normalized hsCRP levels (<2 mg/L), a clinically recognized threshold for reduced cardiovascular risk.
• The drug also demonstrated significant reductions in serum IL-6 (44% median reduction at Day 14) and fibrinogen (30% reduction at Day 14), both key drivers and predictors of cardiovascular events.
• BGE-102 was well tolerated with a favorable safety profile, and no dose-limiting toxicities were observed.
• A patent was issued covering additional composition of matter and a novel NLRP3 binding site for BGE-102.

Sentiment

Score: 8

Explanation: The filing reports strong positive interim Phase 1 clinical trial data for BGE-102, showing significant reductions in key inflammatory markers and a favorable safety profile. The company is advancing the drug to Phase 2a, indicating confidence in the results and potential for a best-in-class oral therapy. The issuance of a new patent also adds to the positive sentiment, suggesting strong intellectual property.

Positives

• BGE-102 achieved an 86% median reduction in hsCRP at Day 14 in obese individuals with elevated hsCRP, demonstrating rapid and profound reduction in inflammatory markers.
• 93% of participants (13 of 14) on BGE-102 achieved hsCRP levels below 2 mg/L at Day 14, the clinically recognized threshold for reduced cardiovascular risk.
• Significant reductions were observed in serum IL-6 (44% median reduction) and fibrinogen (30% reduction), both key drivers and independent predictors of systemic inflammation and cardiovascular events.
• BGE-102 demonstrated potent IL-1 suppression (93% at trough), consistent with strong target engagement.
• The drug was well tolerated with a favorable safety profile, with adverse events being infrequent, mild to moderate, self-limited, and showing no dose-dependent pattern.
• High brain penetration was confirmed, with cerebrospinal fluid concentrations exceeding the IC90 at doses of 60 mg and above.
• A patent was issued covering additional composition of matter and a novel NLRP3 binding site for BGE-102.

Risks

• Ability to develop, obtain regulatory approval for, and commercialize product candidates, including BGE-102.
• Timing and results of preclinical studies and clinical trials, with the risk that positive interim results may not be replicated in subsequent trials or that early-stage success may not predict later-stage results.
• Risks associated with clinical trials, including managing clinical activities, unexpected concerns from additional data, and regulatory authorities requiring more information or delaying/failing to approve drug candidates.
• The occurrence of adverse safety events.
• Failure to protect and enforce intellectual property and other proprietary rights.
• Failure to successfully execute or realize the anticipated benefits of strategic and growth initiatives.
• Risks relating to technology failures or breaches.
• Dependence on collaborators and other third parties for the development of product candidates and other aspects of the business, which are outside of the company's full control.
• Risks associated with current and potential delays, work stoppages, or supply chain disruptions, including due to tariffs and other trade barriers.
• Risks associated with current and potential future healthcare reforms.
• Risks relating to attracting and retaining key personnel.
• Changes in or failure to comply with legal and regulatory requirements, including shifting priorities within the U.S. Food and Drug Administration.
• Risks relating to access to capital and credit markets.
• Other risks and uncertainties detailed under the heading 'Risk Factors' in the company's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025, and other SEC filings.

Future Outlook

The company anticipates completing the Phase 1 trial with full data readout, including two additional MAD cohorts in obese participants with elevated hsCRP, in the first half of 2026. They also plan to initiate a Phase 2a proof-of-concept study in patients with obesity and cardiovascular risk factors in the first half of 2026, with the Phase 2a data readout expected in the second half of 2026.

Management Comments

• "We are very encouraged by these results, which support the potential for BGE-102 to deliver injectable-like inflammation reduction in an oral therapy designed for primary care, the clinical setting where most cardiovascular risk is managed and where oral medicines are preferred by patients and physicians." Kristen Fortney, PhD, CEO and co-founder of BioAge.
• "Chronic inflammation is now recognized as a major driver of cardiovascular disease—on par with cholesterol—yet it remains far less commonly treated. An 86% reduction in hsCRP, with 93% of participants reaching levels associated with reduced cardiovascular risk, positions BGE-102 as a potential best-in-class oral therapy to directly address inflammation." Kristen Fortney, PhD, CEO and co-founder of BioAge.
• "These findings support our plans to advance BGE-102 into a Phase 2a study in the first half of this year." Kristen Fortney, PhD, CEO and co-founder of BioAge.
• "The substantial reductions in hsCRP, IL-6, and fibrinogen we observed in participants with obesity and elevated inflammation demonstrate that BGE-102 potently suppresses the NLRP3-driven inflammatory cascade in a clinically relevant population." Paul Rubin, MD, Chief Medical Officer of BioAge.
• "These data provide strong rationale for advancing into our planned Phase 2a study, where we will evaluate BGE-102's effects on a range of key inflammatory biomarkers over a longer duration in patients with elevated cardiovascular risk." Paul Rubin, MD, Chief Medical Officer of BioAge.

Industry Context

Chronic inflammation is increasingly recognized as a major driver of cardiovascular disease, on par with cholesterol, yet it is often undertreated. An oral therapy like BGE-102, demonstrating significant reduction in key inflammatory markers, could address a substantial unmet medical need, particularly in primary care settings where oral medications are preferred. The NLRP3 pathway is a critical target for age-related inflammation implicated in a broad range of diseases, positioning BGE-102 within a high-interest therapeutic area.

Comparison to Industry Standards

• BGE-102's 86% median reduction in hsCRP and 93% of participants reaching normalized levels (<2 mg/L) positions it as a potential best-in-class oral therapy for inflammation, aiming to deliver 'injectable-like inflammation reduction' in an oral form, which would be a significant advantage over injectable biologics.
• The company highlights that chronic inflammation is a major driver of cardiovascular disease 'on par with cholesterol,' suggesting BGE-102 could target a pathway as critical as those addressed by established lipid-lowering drugs like statins.
• The drug's brain-penetrant nature and novel NLRP3 binding site suggest differentiation from other NLRP3 inhibitors or anti-inflammatory agents currently in development or on the market.

Stakeholder Impact

• Shareholders: The positive clinical data and clear path to Phase 2a could significantly increase investor confidence and potentially the company's valuation, given the large market for cardiovascular risk management.
• Patients with cardiovascular risk factors: BGE-102 offers a potential new, orally available, and highly effective treatment option for chronic inflammation, a major driver of cardiovascular disease, which could improve patient outcomes.
• Healthcare providers: An oral therapy with 'injectable-like' efficacy and a favorable safety profile could be a preferred and more accessible option for managing cardiovascular risk in primary care settings, simplifying treatment regimens.

Next Steps

• Completion of Phase 1 trial with full data readout, including two additional MAD cohorts in obese participants with elevated hsCRP, in 1H 2026.
• Initiation of Phase 2a proof-of-concept study in patients with obesity and cardiovascular risk factors in 1H 2026. This trial will enroll approximately 100 patients randomized 1:1 to BGE-102 monotherapy or placebo for 12 weeks, with the primary endpoint being percent change in hsCRP, and will also assess inflammatory and metabolic biomarkers, including liver MRI.
• Phase 2a data readout in 2H 2026.

Key Dates

Recommendation

The interim Phase 1 data for BGE-102 is exceptionally strong, demonstrating an 86% reduction in hsCRP and 93% of participants reaching normalized levels, along with significant reductions in other critical inflammatory markers. The drug's favorable safety profile, oral administration, and brain-penetrant nature position it as a potential 'best-in-class' therapy for a large and underserved patient population with cardiovascular risk driven by inflammation. The rapid progression to a Phase 2a study and the issuance of a new patent further de-risk the asset and highlight its commercial potential. These results significantly enhance the company's pipeline value and future revenue prospects, warranting a strong buy recommendation for long-term investors.

Keywords

BGE-102, NLRP3 inhibitor, cardiovascular risk, hsCRP, inflammation, Phase 1 clinical trial, obesity, IL-6, fibrinogen, biopharmaceutical, drug development, BioAge Labs